Venus Remedies Ltd has signed an agreement with Pharma Match R&D B.V., a limited company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD dossier for a latest generation carbapenem injectible.

The foreign MNC had approached Venus for collaboration, after its technical team was confident of the company's plants and research facilities. The company would be conducting the complete studies and trials for providing the data for compilation of the EU E-CTD dossier for this carbapenem injectible going off-patent shortly, and Pharma Match, Netherlands would get the same registered in Europe. Pharma Match, Netherlands has been given the exclusive marketing rights for entire European Union to sell this product accompanied by supply agreements with all the potential customers in E. All the profits shall be shared equally between the two collaborators under this agreement.

Work has already started at the company for this project and a highly competent team has been constituted for the CTD dossier compilation work. This product already has good market size globally and the company is expecting to gain a reasonable market share as soon as it goes off patent.